Patents by Inventor Stefan Tomiuk

Stefan Tomiuk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CHIMERIC ANTIGEN RECEPTOR SPECIFIC FOR TUMOR CELLS
    Publication number: 20210085769
    Abstract: The present invention is directed to ligand like a chimeric antigen receptor (CAR), comprising an antigen binding domain specific for one or more antigens selected from the group consisting of CLA, CD142, CD73, CD49c, CD66c, CD104, CD318 and TSPAN8; cell populations expressing such CARs and the use of the cell populations for cancer therapy.
    Type: Application
    Filed: November 11, 2020
    Publication date: March 25, 2021
    Applicant: Miltenyi Biotec B.V. & Co. KG
    Inventors: Dominik Eckardt, Andreas Bosio, Jutta Kollet, Olaf Hardt, Andrzej Dzionek, Stefan Tomiuk
  • CHIMERIC ANITGEN RECEPTOR SPECIFIC FOR TUMOR CELLS
    Publication number: 20200282035
    Abstract: The present invention is directed to ligand like a chimeric antigen receptor (CAR), comprising an antigen binding domain specific for one or more antigens selected from the group consisting of CLA, CD142, CD73, CD49c, CD66c, CD104, CD318 and TSPAN8; cell populations expressing such CARs and the use of the cell populations for cancer therapy.
    Type: Application
    Filed: March 30, 2020
    Publication date: September 10, 2020
    Applicant: Miltenyi Biotec B.V. & Co. KG
    Inventors: Dominik Eckardt, Andreas Bosio, Jutta Kollet, Olaf Hardt, Andrzej Dzionek, Stefan Tomiuk
  • Chimeric antigen receptor specific for tumor cells
    Patent number: 10617720
    Abstract: The present invention is directed to ligand like a chimeric antigen receptor (CAR), comprising an antigen binding domain specific for one or more antigens selected from the group consisting of CLA, CD142, CD73, CD49c, CD66c, CD104, CD318 and TSPAN8; cell populations expressing such CARs and the use of the cell populations for cancer therapy.
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: April 14, 2020
    Assignee: Miltenyi Biotech, GmbH
    Inventors: Dominik Eckardt, Andreas Bosio, Olaf Hardt, Andrzej Dzionek, Stefan Tomiuk, Jutta Kollet
  • Chimeric antigen receptor specific for tumor cells
    Publication number: 20190209611
    Abstract: The present invention is directed to ligand like a chimeric antigen receptor (CAR), comprising an antigen binding domain specific for one or more antigens selected from the group consisting of CLA, CD142, CD73, CD49c, CD66c, CD104, CD318 and TSPAN8; cell populations expressing such CARs and the use of the cell populations for cancer therapy.
    Type: Application
    Filed: October 17, 2017
    Publication date: July 11, 2019
    Applicant: Miltenyi Biotec GmbH
    Inventors: Dominik Eckardt, Andreas Bosio, Olaf Hardt, Andrzej Dzionek, Stefan Tomiuk, Jutta Kollet
  • Humanized antibody or fragment thereof specific for CD45R0
    Patent number: 9701756
    Abstract: The present invention provides a humanized antibody or fragment thereof specific for the antigen CD45R0, wherein said antibody or fragment thereof comprises a humanized heavy chain variable domain comprising a CDR1 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2, and a CDR3 region of SEQ ID NO:3, and a humanized light chain variable domain comprising a CDR1 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5, and a CDR3 region of SEQ ID NO:6. It is also provided the use of the present antibody or fragment thereof for enrichment or depletion of CD45R0-expressing cells from a sample comprising CD45R0-expressing cells.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: July 11, 2017
    Assignee: Miltenyi Biotec GmbH
    Inventors: Holger Thie, Stefan Tomiuk, Iris Bürger, Volker Nolle
  • HUMANIZED ANTIBODY OR FRAGMENT THEREOF SPECIFIC FOR CD45R0
    Publication number: 20160152733
    Abstract: The present invention provides a humanized antibody or fragment thereof specific for the antigen CD45R0, wherein said antibody or fragment thereof comprises a humanized heavy chain variable domain comprising a CDR1 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2, and a CDR3 region of SEQ ID NO:3, and a humanized light chain variable domain comprising a CDR1 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5, and a CDR3 region of SEQ ID NO:6. It is also provided the use of the present antibody or fragment thereof for enrichment or depletion of CD45R0-expressing cells from a sample comprising CD45R0-expressing cells.
    Type: Application
    Filed: November 25, 2015
    Publication date: June 2, 2016
    Inventors: Holger THIE, Stefan Tomiuk, Iris Bürger, Volker Nolle
  • METHOD OF DETERMINING KIDNEY TRANSPLANTATION TOLERANCE
    Publication number: 20130143223
    Abstract: The present invention relates to a method of determining an individual's transplantation tolerance by determining the level of a number of biomarkers. The present invention also relates to a kit comprising reagents for detecting the levels of the biomarkers. The present invention also relates to a sensor for detecting the expression levels of a plurality of genes that can be used to determine an individual's transplantation tolerance.
    Type: Application
    Filed: May 4, 2011
    Publication date: June 6, 2013
    Inventors: Maria Hernandez-Fuentes, Irene Rebollo-Mesa, Uwe Janssen, Stefan Tomiuk, Birgit Sawitzki, Hans-Dieter Volk, Robert Lechler